Have you tried to stop Pristiq only to suffer Pristiq Withdrawal symptoms? Are you looking for help to stop Pristiq interested in a holistic approach to withdrawal and healing? Our nonprofit has helped people in 78 countries to Stop Pristiq over the last 15 years. Our success is unmatched and our team kind, knowledgeable and dedicated. Pristiq has a higher rate of withdrawal symptoms than other SNRI or SSRI antidepressants. Let us help you Taper Pristiq while diminishing the Pristiq Withdrawal Symptoms naturally. Contact our Prescription Experts today for a free consultation.
SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW
From the moment I discovered your life-saving withdrawal program, I felt understood and really cared for.
- Suzy (Pristiq Withdrawal Success Story)
Enter Discount Code ADFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only
Our Pristiq weaning program is a slow taper that allows you to safely step down from Pristiq under the guidance of our Prescription Experts, your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Pristiq until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help minimize Pristiq withdrawal symptoms to improve mental and physical well-being.
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Pristiq Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Pristiq alone, work with our Prescription Drug Experts.
Imagine being Free of Pristiq Addiction
- Proven Program completed In-Home with Expert Guidance
- Slowly Wean off Pristiq
- All-Natural Nutraceuticals to help Ease Pristiq Withdrawal Symptoms
- Professional information on interactions
- Free Mentoring on our 24/7 private Discussion Board
- Free Assessment Upon Starting our Program (a $400 value)
WITHDRAWAL SUCCESS STORIES
I really appreciate the gift of being able to be off the SSRI's because of the negative side effects they had. Thank you!!! More...
I am drug-free now and my mind is clear and sharp. The nerve pain is much, better and my life is full. I plan to continue taking the nutrients forever.
I didn't know what a fighter I was until now that I look back on this past year and realize that I never once thought about quitting the program.
Here I am at the other side, I've returned to my life but it's better than it was before because I have such gratitude and appreciation for all that I have.
—Suzy (Pristiq Withdrawal Success Story)
Pristiq Info and History
Pristiq was approved by the FDA in 2007 (for Wyeth Laboratories) and is the active metabolite of Venlafaxine (Effexor), which lost its patent protection the same year. Desvenlafaxine was approved in Canada and the United States,
but the European Union declined stating in part, "they had some concerns and was of the provisional opinion that Desvenlafaxine could not have been approved for the treatment of major depressive disorder [and] overall,
the effectiveness of Desvenlafaxine had not been shown convincingly. In relation to its parent substance, Venlafaxine, Desvenlafaxine seemed to be less effective with no advantages in terms of safety and tolerability."
Wyeth withdrew its application for approval in the European Union.
In December 2015 Pfizer announced the results from a Phase 3 study evaluating the efficacy, safety and tolerability of Pristiq (sustained release) in pediatric patients ages 7-17 with Major Depressive Disorder. The results indicate that Pristiq (Desvenlafaxine) were not significantly different from placebo.
Pristiq has higher rates of withdrawal symptoms (discontinuation syndrome) than other SNRI or SSRI antidepressants. For some patients the symptoms can be severe and are considered intolerable. A gradual taper is recommended to minimize symptoms.
Pristiq Withdrawal Symptoms, Side Effects, Adverse Reactions
PRISTIQ WITHDRAWAL SYMPTOMS MAY INCLUDE:
aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression
PRISTIQ SIDE EFFECTS MAY INCLUDE:
allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives), irregular heartbeat or pulse, low blood pressure (dizziness, weakness), high blood pressure (severe headache, blurred vision), chills or fever, unusual bleeding or bruising, rash or hives, Suicidal Ideation, Headache, tremor, nervousness, or anxiety; difficulty concentrating, constipation, nausea, diarrhea, dry mouth, or changes in appetite or weight, weakness, increased sweating, sleeping or insomnia, decreased sex drive, impotence, or difficulty having an orgasm
PRISTIQ ADVERSE REACTIONS MAY INCLUDE: per PDR
Severe: seizures, angioedema, pancreatitis, suicidal ideation, SIADH, GI bleeding, cardiomyopathy, myocardial infarction, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, eosinophilic pneumonia, serotonin syndrome, neonatal abstinence syndrome
Moderate: withdrawal, constipation, impotence, hypercholesterolemia, orthostatic hypotension, proteinuria, ejaculation dysfunction, hypertriglyceridemia, blurred vision, hypertension, dystonic reaction, teeth grinding (bruxism), sinus tachycardia, urinary retention, hyperprolactinemia, elevated hepatic enzymes, peripheral vasodilation, mania, hallucinations, depression, akathisia, impulse control symptoms, hostility, hyponatremia, platelet dysfunction, hematoma, bleeding, dyspnea
Mild: nausea, xerostomia, hyperhidrosis, dizziness, insomnia, drowsiness, fatigue, anore, anxiety, abnormal dreams, yawning, chills, weight gain, dysgeusia, syncope, photosensitivity, rash, a lopecia, t innitus, flushing, musculoskeletal pain, asthenia, weight loss, i rritability, restlessness, ecchymosis, p etechiae, cough
PRISTIQ BOXED WARNINGS: per PDR
Pristiq is not FDA approved for the treatment of major depressive disorder (MDD) in children or adolescents. Efficacy in MDD was not demonstrated in two 8-week controlled trials of 587 pediatric patients 7 to 17 years of age. In addition, more patients receiving Pristiq than placebo had a decrease in body weight of 3.5% or greater from their baseline weight (14% to 22% vs. 7%). During long-term extension studies in the same population, the mean changes in weight approximated expected changes based on data from age and gender-matched controls. In October 2004, the FDA directed manufacturers of all antidepressants to add a boxed warning to their product labels detailing the risk of suicide in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in pediatrics or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or during dose changes. It is unknown if the suicidality risk in children or young adults extends to longer-term therapy. The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment should be closely monitored during treatment with Pristiq. In patients who exhibit worsening of depression or suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management to reduce the risk of overdose.
Pristiq References and Information
According to the FDA:
Clinical Worsening/Suicide Risk: Monitor for clinical worsening and suicide risk
Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions: Serotonin syndrome or NMS-like reactions have been reported with SSRIs and SNRIs. Discontinue Pristiq and initiate supportive treatment.
Elevated Blood Pressure: Has occurred with Pristiq. Hypertension should be controlled before initiating treatment. Monitor blood pressure regularly during treatment
Abnormal Bleeding: Pristiq may increase the risk of bleeding events. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Pristiq and NSAIDs, aspirin, or other drugs that affect coagulation
Narrow-angle Glaucoma: Mydriasis has occurred with Pristiq. Patients with raised intraocular pressure or those at risk of angle-closure glaucoma should be monitored
Activation of Mania/Hypomania: Has occurred. Use cautiously in patients with Bipolar Disorder. Caution patients about the risk of activation of mania/hypomania
Cardiovascular/Cerebrovascular Disease: Use cautiously in patients with cardiovascular or cerebrovascular disease
Cholesterol and Triglyceride Elevation: Have occurred. Use cautiously in patients with lipid metabolism disorders. Consider monitoring serum cholesterol and triglyceride
Discontinuation Symptoms: Have occurred. Taper the dose when possible and monitor for discontinuation symptoms
Renal Impairment: Reduces the clearance of Pristiq. Dosage adjustment is necessary in severe and ESRD. In moderate renal impairment, the dose should not exceed 50 mg/day
Seizure: Can occur. Use cautiously in patients with seizure disorder
Hyponatremia: Can occur in association with SIADH
Drugs Containing Desvenlafaxine or Venlafaxine: Should not be used concomitantly with Pristiq
Interstitial Lung Disease and Eosinophilic Pneumonia: Can occur
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
* Testimonial results may vary person to person.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with your physician to help you with your drug withdrawal process and with his or her consent.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support. More..